share_log

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $19.57

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $19.57

CRinetics制药公司(纳斯达克代码：CRNX)股价下跌至19.57美元
Financial News Live ·  2022/09/22 14:41

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) shares gapped down prior to trading on Thursday . The stock had previously closed at $19.57, but opened at $18.89. Crinetics Pharmaceuticals shares last traded at $18.89, with a volume of 302 shares traded.

Crinetics制药公司(纳斯达克代码：CRNX-GET评级)的股价在周四交易前大幅下跌。该股此前收盘报19.57美元，开盘报18.89美元。Crinetics PharmPharmticals的股票尾盘报18.89美元，成交量为302股。

Analyst Upgrades and Downgrades

分析师升级和下调评级

Separately, SVB Leerink upped their target price on shares of Crinetics Pharmaceuticals from $36.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, May 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $39.67.

另外，SVB Leerink在5月26日(星期四)的一份报告中将Crinetics PharmPharmticals的目标价从36.00美元上调至39.00美元，并给予该股“跑赢大盘”的评级。根据MarketBeat的数据，五位分析师对该股的评级为买入，共识评级为买入，平均目标价为39.67美元。

Get
到达
Crinetics Pharmaceuticals
Crinetics制药公司
alerts:
警报：

Crinetics Pharmaceuticals Price Performance

Crinetics药品价格表现

The stock has a market capitalization of $1.02 billion, a PE ratio of -6.63 and a beta of 1.20. The stock's 50 day simple moving average is $20.57 and its two-hundred day simple moving average is $20.13.

该股市值10.2亿美元，市盈率为-6.63，贝塔系数为1.20。该股的50日简单移动均线切入位为20.57美元，200日简单移动均线切入位为20.13美元。

Insider Buying and Selling at Crinetics Pharmaceuticals

Crinetics PharmPharmticals的内幕买卖

In other news, insider Stephen F. Betz sold 4,168 shares of the business's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $21.01, for a total value of $87,569.68. Following the sale, the insider now owns 100,598 shares of the company's stock, valued at $2,113,563.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through
在其他新闻方面，内部人士斯蒂芬·F·贝茨在9月15日星期四的一次交易中出售了4168股该公司的股票。这些股票的平均价格为21.01美元，总价值为87,569.68美元。出售后，这位内部人士现在拥有100,598股该公司股票，价值2,113,563.98美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
the SEC website
美国证券交易委员会网站
. In other news, Director Matthew K. Fust sold 5,700 shares of the business's stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total value of $119,472.00. Following the sale, the director now owns 12,536 shares of the company's stock, valued at $262,754.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through
。在其他新闻方面，董事马修·K·福斯特在7月13日(星期三)的一笔交易中出售了5,700股该公司股票。这些股票的平均价格为20.96美元，总价值为119,472.00美元。出售后，董事现在拥有12536股该公司的股票，价值262,754.56美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
the SEC website
美国证券交易委员会网站
. Also, insider Stephen F. Betz sold 4,168 shares of the business's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $21.01, for a total transaction of $87,569.68. Following the transaction, the insider now directly owns 100,598 shares of the company's stock, valued at approximately $2,113,563.98. The disclosure for this sale can be found
。此外，内部人士斯蒂芬·F·贝茨在9月15日星期四的一次交易中出售了4168股该公司的股票。这些股票以21.01美元的平均价格出售，总成交金额为87,569.68美元。交易完成后，这位内部人士现在直接持有该公司100,598股股票，价值约2,113,563.98美元。关于这次销售的披露可以找到
here
这里
. Insiders have sold a total of 12,062 shares of company stock worth $252,770 over the last three months. 5.90% of the stock is currently owned by insiders.
。过去三个月，内部人士总共出售了12,062股公司股票，价值252,770美元。该公司5.90%的股份目前由内部人士持有。

Hedge Funds Weigh In On Crinetics Pharmaceuticals

对冲基金买入Crinetics制药公司

Several hedge funds have recently bought and sold shares of the company. Federated Hermes Inc. grew its stake in Crinetics Pharmaceuticals by 2.6% during the first quarter. Federated Hermes Inc. now owns 25,482 shares of the company's stock valued at $559,000 after acquiring an additional 646 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Crinetics Pharmaceuticals by 9.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,300 shares of the company's stock valued at $215,000 after acquiring an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Crinetics Pharmaceuticals by 17.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after acquiring an additional 1,110 shares in the last quarter. American International Group Inc. grew its stake in Crinetics Pharmaceuticals by 7.6% in the 2nd quarter. American International Group Inc. now owns 24,630 shares of the company's stock worth $459,000 after buying an additional 1,749 shares in the last quarter. Finally, Group One Trading L.P. increased its holdings in shares of Crinetics Pharmaceuticals by 31.6% in the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock worth $161,000 after buying an additional 1,759 shares during the last quarter. Hedge funds and other institutional investors own 94.42% of the company's stock.

几家对冲基金最近买卖了该公司的股票。今年第一季度，联合爱马仕公司在Crinetics PharmPharmticals的持股增加了2.6%。联合爱马仕公司目前持有25,482股该公司股票，价值55.9万美元，该公司在上个季度增持了646股。第一季度，德意志银行在Crinetics PharmPharmticals的持股增加了9.7%。在上个季度增持了1,000股德意志银行股票后，德意志银行现在持有11,300股该公司股票，价值21.5万美元。Zurcher Kantonalbank苏黎世广东银行第一季度增持Crinetics PharmPharmticals股份17.4%。Zurcher Kantonalbank苏黎世广东银行在上个季度增持了1110股后，现在拥有7493股该公司股票，价值16.4万美元。美国国际集团(American International Group Inc.)在第二季度增持了Crinetics PharmPharmticals 7.6%的股份。美国国际集团(American International Group Inc.)目前持有24,630股该公司股票，价值45.9万美元，该公司在上个季度又购买了1,749股。最后，Group One Trading L.P.在第一季度增持了Crinetics PharmPharmticals的股票31.6%。Group One Trading L.P.现在持有该公司7318股股票，价值16.1万美元，在上个季度又购买了1759股。对冲基金和其他机构投资者持有该公司94.42%的股票。

About Crinetics Pharmaceuticals

关于Crinetics制药公司

(Get Rating)

(获取评级)

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

Crinetics制药公司是一家临床阶段制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤治疗药物的发现、开发和商业化。它的主要候选产品是Paltusotine，这是一种口服选择性非肽生长抑素受体2型激动剂，已经完成了治疗肢端肥大症的第三阶段临床试验，以及治疗类癌综合征和无功能神经内分泌肿瘤(NETS)的第二阶段临床试验。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Is The Golden Age Of Homebuilding Already Over?
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免费获取StockNews.com的Crinetics PharmPharmticals研究报告(CRNX)
  • 斯蒂尔凯斯的收益说明了他重返办公室的原因吗？
  • 这些机构持有达顿餐饮国际公司的股份
  • 这三大股利支付者也拥有强劲的价格增长
  • 住房建设的黄金时代已经结束了吗？
  • 天然气价格继续回升，这些股票应该会受益

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

获得《Crinetics PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Crinetics制药和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发